MA27085A1 - Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens - Google Patents
Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiensInfo
- Publication number
- MA27085A1 MA27085A1 MA27689A MA27689A MA27085A1 MA 27085 A1 MA27085 A1 MA 27085A1 MA 27689 A MA27689 A MA 27689A MA 27689 A MA27689 A MA 27689A MA 27085 A1 MA27085 A1 MA 27085A1
- Authority
- MA
- Morocco
- Prior art keywords
- cephalosporin
- cats
- dogs
- treatment
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 30 Novembre 2001 60/338,536 US 26 Juillet 2002 60/398,932 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulations comprenant une céphalosporine et leur utilisation dans le traitement d'infections bactériennes chez les chats et les chiens Formulations contenant un sel anti-bactérien de métal alcalin d'une céphalosporine, et méthodes pour le traitement ou la prévention d'infections bactériennes chez des chiens et des chats.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33853601P | 2001-11-30 | 2001-11-30 | |
US39893202P | 2002-07-26 | 2002-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27085A1 true MA27085A1 (fr) | 2004-12-20 |
Family
ID=26991236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27689A MA27085A1 (fr) | 2001-11-30 | 2004-05-20 | Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens |
Country Status (28)
Country | Link |
---|---|
US (1) | US7378408B2 (fr) |
EP (1) | EP1448234B1 (fr) |
JP (1) | JP4689959B2 (fr) |
KR (1) | KR100621291B1 (fr) |
CN (1) | CN100502873C (fr) |
AR (1) | AR037595A1 (fr) |
AT (1) | ATE406916T1 (fr) |
AU (1) | AU2002348986B2 (fr) |
BR (1) | BRPI0214583B1 (fr) |
CA (1) | CA2468708C (fr) |
CY (1) | CY1108437T1 (fr) |
DE (1) | DE60228749D1 (fr) |
DK (1) | DK1448234T3 (fr) |
EA (1) | EA008503B1 (fr) |
ES (1) | ES2307800T3 (fr) |
HK (1) | HK1071292A1 (fr) |
HR (1) | HRP20040487A2 (fr) |
IL (2) | IL161851A0 (fr) |
IS (1) | IS7214A (fr) |
MA (1) | MA27085A1 (fr) |
MX (1) | MXPA04003724A (fr) |
NO (1) | NO334818B1 (fr) |
NZ (1) | NZ532208A (fr) |
PL (1) | PL212683B1 (fr) |
PT (1) | PT1448234E (fr) |
TN (1) | TNSN04097A1 (fr) |
TW (1) | TWI248363B (fr) |
WO (1) | WO2003045435A1 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
ES2292122T3 (es) * | 2004-04-22 | 2008-03-01 | Pfizer Products Incorporated | Procedimiento de estabilizacion de sal sodica de cefovecina desordenada. |
EP1656930A1 (fr) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Formulation lyophilisée stabilisée pour des dérivés des céphalosporines |
JP2008524204A (ja) * | 2004-12-17 | 2008-07-10 | ヴィーナス・レメディーズ・リミテッド | 感染の処置に全面的解決を与えるための抗生物質の組合せ |
KR20070085674A (ko) * | 2005-02-14 | 2007-08-27 | 비너스 레머디스 리미티드 | 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 |
EP1945223B1 (fr) * | 2005-10-29 | 2010-07-07 | Intervet International BV | Compositions de cefquinome et procédés d'utilisation de celles-ci |
US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
AU2009222020A1 (en) * | 2008-03-04 | 2009-09-11 | Elan Pharma International Limited | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US8725420B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
US8545856B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US8731841B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8731840B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8788211B2 (en) * | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US20100111857A1 (en) | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US20110150765A1 (en) | 2008-10-31 | 2011-06-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Frozen compositions and methods for piercing a substrate |
KR102329764B1 (ko) * | 2013-03-15 | 2021-11-23 | 머크 샤프 앤드 돔 코포레이션 | 세프톨로잔 항균성 조성물 |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
PL3319596T3 (pl) * | 2015-07-09 | 2024-04-15 | Uniwell Laboratories Llc | Farmaceutyczne kompozycje |
US10966929B2 (en) | 2015-09-07 | 2021-04-06 | Mochida Pharmaceutical Co., Ltd. | Freeze-dried alginic acid preparation |
EP3687993A1 (fr) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Formes pharmaceutiques de dérivés de diazabicyclooctane et leur procédé de fabrication |
JP2020535212A (ja) | 2017-09-27 | 2020-12-03 | フェドラ・ファーマシューティカルズ・インコーポレイテッドFedora Pharmaceuticals Inc. | ジアザビシクロオクタン誘導体の結晶型及びその生産プロセス |
US10682413B2 (en) | 2017-09-27 | 2020-06-16 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same |
GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
CN109393004A (zh) * | 2018-09-28 | 2019-03-01 | 上海锦立保鲜科技有限公司 | 一种利用冻品自由水升华实现真空解冻的方法 |
CA3240020A1 (fr) * | 2021-11-26 | 2023-06-01 | Astellas Pharma Inc. | Composition pharmaceutique solide contenant un compose d'indocyanine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002748A (en) * | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
JPS6045514A (ja) * | 1983-08-22 | 1985-03-12 | Shionogi & Co Ltd | 安定な抗菌性凍結乾燥製剤 |
SE8500273D0 (sv) * | 1985-01-22 | 1985-01-22 | Leo Ab | Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
US5138066A (en) * | 1987-08-14 | 1992-08-11 | Hoffmann-La Roche, Inc. | Intermediates for cephalosporins with sulfur-containing oxyimino side chain |
NZ227842A (en) | 1988-02-05 | 1990-12-21 | Lilly Co Eli | Crystalline 2.5-hydrate form of a beta-lactam |
NO903844L (no) * | 1989-09-05 | 1991-03-06 | Neophore Tech Inc | Medikamentavgivelsesblandinger basert paa biologiske celler eller komponenter derav og fremgangsmaater. |
US6020329A (en) * | 1990-07-24 | 2000-02-01 | Pzifer Inc. | Cephaloporins and homologues, preparations and pharmaceutical compositions |
MY106399A (en) * | 1990-07-24 | 1995-05-30 | Pfizer | Cephalosporins and homologeus, preparation and pharmaceutical composition |
US6001997A (en) * | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
EP0664117A1 (fr) * | 1994-01-25 | 1995-07-26 | F. Hoffmann-La Roche Ag | Solutions de liposomes |
US5665760A (en) * | 1995-09-18 | 1997-09-09 | Sanofi Winthrop, Inc. | Lyophilized thioxanthenone antitumor agents |
KR100312622B1 (ko) * | 1998-11-03 | 2002-02-28 | 김송배 | 생약을주성분으로한안정화된항암제조성물및그제조방법 |
JP2001199889A (ja) * | 1999-11-11 | 2001-07-24 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体を含有してなる点鼻用剤 |
ATE311227T1 (de) | 1999-12-01 | 2005-12-15 | Natco Pharma Ltd | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne |
GB0002835D0 (en) * | 2000-02-09 | 2000-03-29 | Melvin William T | Drug resistance in cancer |
GB0019124D0 (en) | 2000-08-03 | 2000-09-27 | Pfizer | Novel process |
CA2436848C (fr) * | 2000-12-04 | 2008-12-02 | Pfizer Products Inc. | Procede de couplage et produits intermediaires utiles pour la preparation de cephalosporines |
-
2002
- 2002-11-12 US US10/292,343 patent/US7378408B2/en not_active Expired - Lifetime
- 2002-11-13 IL IL16185102A patent/IL161851A0/xx unknown
- 2002-11-13 EP EP02781499A patent/EP1448234B1/fr not_active Expired - Lifetime
- 2002-11-13 NZ NZ532208A patent/NZ532208A/en not_active IP Right Cessation
- 2002-11-13 WO PCT/IB2002/004743 patent/WO2003045435A1/fr active IP Right Grant
- 2002-11-13 AT AT02781499T patent/ATE406916T1/de active
- 2002-11-13 DK DK02781499T patent/DK1448234T3/da active
- 2002-11-13 MX MXPA04003724A patent/MXPA04003724A/es active IP Right Grant
- 2002-11-13 KR KR1020047008097A patent/KR100621291B1/ko active Protection Beyond IP Right Term
- 2002-11-13 CA CA002468708A patent/CA2468708C/fr not_active Expired - Lifetime
- 2002-11-13 EA EA200400489A patent/EA008503B1/ru unknown
- 2002-11-13 PT PT02781499T patent/PT1448234E/pt unknown
- 2002-11-13 DE DE60228749T patent/DE60228749D1/de not_active Expired - Lifetime
- 2002-11-13 AU AU2002348986A patent/AU2002348986B2/en not_active Expired
- 2002-11-13 BR BRPI0214583A patent/BRPI0214583B1/pt active IP Right Grant
- 2002-11-13 ES ES02781499T patent/ES2307800T3/es not_active Expired - Lifetime
- 2002-11-13 CN CNB028229258A patent/CN100502873C/zh not_active Expired - Lifetime
- 2002-11-13 JP JP2003546936A patent/JP4689959B2/ja not_active Expired - Lifetime
- 2002-11-13 PL PL370083A patent/PL212683B1/pl unknown
- 2002-11-19 TW TW091133707A patent/TWI248363B/zh not_active IP Right Cessation
- 2002-11-28 AR ARP020104594A patent/AR037595A1/es not_active Application Discontinuation
-
2004
- 2004-04-07 IS IS7214A patent/IS7214A/is unknown
- 2004-05-06 IL IL161851A patent/IL161851A/en active IP Right Grant
- 2004-05-20 MA MA27689A patent/MA27085A1/fr unknown
- 2004-05-28 TN TNP2004000097A patent/TNSN04097A1/fr unknown
- 2004-05-31 HR HR20040487A patent/HRP20040487A2/hr not_active Application Discontinuation
- 2004-06-01 NO NO20042271A patent/NO334818B1/no not_active IP Right Cessation
-
2005
- 2005-05-13 HK HK05104040.7A patent/HK1071292A1/xx not_active IP Right Cessation
-
2008
- 2008-10-21 CY CY20081101180T patent/CY1108437T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27085A1 (fr) | Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens | |
TNSN05202A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant | |
MA26770A1 (fr) | Diarylamines substituees par 1-heterocycle. | |
MA28003A1 (fr) | [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie | |
MA25009A1 (fr) | Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes | |
MA25775A1 (fr) | Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires. | |
GEP20053429B (en) | 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents | |
HUP0203619A2 (hu) | Moxifloxacint és konyhasót tartalmazó készítmény és eljárás az előállítására | |
TW200734344A (en) | Antibacterial agents | |
WO2000034265A3 (fr) | Agents antimicrobiens quinoleine-indole, et utilisations et compositions associees | |
ZA200507070B (en) | Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections | |
EP1594444A3 (fr) | Methodes et compositions destinees au traitement et a la prevention d'infections a staphylocoque ou autres infections bacteriennes | |
DE60041753D1 (de) | Arzneimittel zur behandlung von c. pneumoniae infektionen | |
ATE335499T1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
MA26703A1 (fr) | Macrolides antibiotiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
YU102503A (sh) | Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva | |
MA27021A1 (fr) | Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant | |
WO2005054234A8 (fr) | Piperidino phenyloxazolidinones substituees dont l'activite antimicrobienne a un meilleur rendement in vivo | |
ATE417915T1 (de) | Reinigungsaktive und desinfizierende zusammensetzung | |
CO5251446A1 (es) | Mezcla de linezolid y otros agentes antibacterianos | |
TNSN00103A1 (fr) | Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
FR2800614B1 (fr) | Composition pour le traitement des infections des voies respiratoires | |
AU4568400A (en) | Sphingomyelinase inhibitor | |
WO2001077365A3 (fr) | Procedes et materiaux antimicrobiens | |
MA27864A1 (fr) | Composition pharmaceutique pour l'administration par voie nasale de piribedil |